Research partially funded by the JKTG Foundation recently appeared recently in the Bulletin of Mathematical Biology.
The research, Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer, includes work by Heiko Enderling, Ph.D., a researcher with whom JKTG has worked on several projects.
As described in the published abstract, first-line therapy for prostate cancer includes androgen deprivation therapy (ADT), depriving both the normal and malignant prostate cells of androgens required for proliferation and survival.
In recent years, intermittent ADT has been proposed as an alternative to continuous ADT. Several mathematical models with different biological resistance mechanisms have been considered to simulate intermittent ADT response dynamics.
The research compares 13 intermittent dynamical models and assess their ability to describe prostate-specific antigen (PSA) dynamics.
The Jayne Koskinas Ted Giovanis Foundation for Health and Policy (JKTG Foundation) today announced funding to develop a prototype multiscale model designed to predict therapeutic responses of tumor ecosystems – a new frontier in breast cancer research.
The word “stakeholder” really bothers me particularly in the healthcare space. I’m struck by a quote by Ken Burns.
“The thing that I’ve learned is that there is no ‘them.’ This is what everybody does: make a distinction about ‘them.’ It’s just ‘us’.”
In racing, we measure this in lap times often down to the second or tenths of a second. A recent racing article provoked me to think about the pursuit of “the last tenth” of a second in improvement which is typically the toughest and most difficult to attain.